Skip to main content
logo
Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0319
+0.0019 (6.33%)
Jul 31, 2026, 9:52 AM EST

Adaptimmune Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
5.925.92-60.2827.156.15
Revenue Growth
-95.58%--122.05%341.50%55.36%
Gross Profit
2.545.92-60.2827.156.15
Operating Income
-174.67-77.69-178.32-159.66-163.97-162.25
Net Income
-77.9225.21-77.92-144.54-165.46-158.09
Earnings Per Share
0.020.02-0.04-0.10-0.17-0.17
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
25.9525.95151.61146.94204.61369.58
Total Debt
14.0814.0874.2925.3323.3727.06
Net Cash (Debt)
11.8711.8777.32121.61181.23342.52
Net Cash Growth
-84.65%-84.65%-36.42%-32.90%-47.09%-0.58%
Net Cash Per Share
0.010.010.040.100.190.37

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-121.91-121.91-69.12-137.27-141.7713.69
Capital Expenditures
-0.39-0.39-0.89-4.68-29.5-8.57
Free Cash Flow
-122.3-122.3-70-141.95-171.275.12
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
42.94%100.00%-100.00%100.00%100.00%
Operating Margin
-2948.51%-1311.39%--264.86%-603.97%-2638.58%
Pretax Margin
-1316.78%-1316.78%--217.00%-600.26%-2558.12%
Profit Margin
-1296.74%-1316.78%--239.77%-591.06%-2545.26%
FCF Margin
-2064.40%-2064.40%--235.49%-630.86%83.20%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
0.361.30----
P/FCF Ratio
-----687.22
PS Ratio
1.526.98-17.9353.09571.77